Pdt Partners, LLC Vericel Corp Transaction History

Pdt Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$22.88 - $39.45 $919,066 - $1.58 Million	40,169 Added 327.88%	52,420 $1.32 Million
Q1 2022 May 16, 2022	SELL	$31.69 - $43.29 $1.34 Million - $1.83 Million	-42,227 Reduced 77.51%	12,251 $468,000
Q4 2021 Feb 14, 2022	SELL	$35.2 - $52.6 $877,817 - $1.31 Million	-24,938 Reduced 31.4%	54,478 $2.14 Million
Q3 2021 Nov 15, 2021	BUY	$46.35 - $59.75 $172,282 - $222,090	3,717 Added 4.91%	79,416 $3.88 Million
Q2 2021 Aug 16, 2021	BUY	$47.2 - $67.81 $61,312 - $88,085	1,299 Added 1.75%	75,699 $3.97 Million
Q1 2021 May 17, 2021	BUY	$30.93 - $59.48 $42,219 - $81,190	1,365 Added 1.87%	74,400 $4.13 Million
Q4 2020 Feb 16, 2021	SELL	$18.53 - $31.5 $171,810 - $292,068	-9,272 Reduced 11.27%	73,035 $2.26 Million
Q3 2020 Nov 16, 2020	SELL	$14.68 - $19.12 $140,883 - $183,494	-9,597 Reduced 10.44%	82,307 $1.53 Million
Q2 2020 Aug 14, 2020	SELL	$8.5 - $15.82 $208,879 - $388,760	-24,574 Reduced 21.1%	91,904 $1.27 Million
Q1 2020 May 15, 2020	BUY	$7.25 - $19.22 $442,409 - $1.17 Million	61,022 Added 110.04%	116,478 $1.07 Million
Q4 2019 Feb 14, 2020	BUY	$13.77 - $19.2 $763,629 - $1.06 Million	55,456 New	55,456 $965,000

279

48.7M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.76B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.